tiprankstipranks
Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Canadian Market

Crescita Therpeutc (CTX) AI Stock Analysis

Compare
13 Followers

Top Page

TS

Crescita Therpeutc

(TSX:CTX)

54Neutral
Crescita Therapeutics' overall stock score reflects significant challenges in financial performance, particularly in profitability and revenue growth. While the technical analysis shows some positive momentum, the negative valuation metrics weigh heavily. The absence of earnings call insights and corporate events means the focus remains on addressing core financial weaknesses.

Crescita Therpeutc (CTX) vs. S&P 500 (SPY)

Crescita Therpeutc Business Overview & Revenue Model

Company DescriptionCrescita Therapeutics Inc. (CTX) is a publicly traded, Canadian commercial dermatology company that operates in the life sciences sector. The company focuses on the development and commercialization of non-prescription skincare products and prescription drug products with a primary focus on the treatment of skin conditions. Crescita leverages its patented transdermal delivery technologies to enhance the efficacy of its products.
How the Company Makes MoneyCrescita Therapeutics generates revenue through multiple streams, primarily from the sale of its skincare and therapeutic products. The company distributes non-prescription skincare solutions across various retail and online channels, targeting both individual consumers and professional dermatology markets. Additionally, Crescita licenses its proprietary transdermal delivery technologies to other pharmaceutical companies, earning royalties and milestone payments. The company may also engage in partnerships and collaborations with other entities to co-develop and commercialize new therapeutic products, further contributing to its revenue. Crescita's earnings are influenced by its ability to innovate and expand its product portfolio, as well as its strategic alliances within the industry.

Crescita Therpeutc Financial Statement Overview

Summary
Crescita Therapeutic faces significant financial challenges, particularly in terms of profitability and revenue growth. While the balance sheet is stable with low leverage, negative profitability metrics weigh down the overall financial health. Improvements in operational efficiency and profitability are needed.
Income Statement
45
Neutral
Crescita Therapeutic's income statement indicates a decline in revenue and profitability. The TTM (Trailing-Twelve-Months) revenue fell slightly compared to the previous year, and the company has experienced negative EBIT and net income margins, suggesting ongoing operational challenges. The revenue growth rate is negative, reflecting a contraction from prior periods.
Balance Sheet
70
Positive
The balance sheet reflects a moderate level of stability with a healthy equity base. Although the debt-to-equity ratio is low, indicating conservative leverage, the return on equity is negative due to recent losses. Despite this, the company maintains a strong equity ratio, highlighting a solid asset base relative to liabilities.
Cash Flow
50
Neutral
The cash flow analysis shows a mixed picture. Operating cash flow remains positive, which is a good sign of operational cash generation. However, the free cash flow is negative in the TTM, indicating that capital expenditures may exceed operating cash flow. This could signal potential liquidity challenges if sustained.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
17.40M17.52M23.52M16.77M15.64M22.34M
Gross Profit
8.91M10.36M13.18M10.01M11.27M16.54M
EBIT
-3.06M-1.96M732.00K-529.00K2.51M3.97M
EBITDA
-1.26M45.00K2.09M598.00K2.26M5.59M
Net Income Common Stockholders
-2.74M-1.99M862.00K-1.10M37.00K1.85M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.59M9.38M8.24M11.33M14.28M9.27M
Total Assets
27.57M24.60M28.48M28.92M26.83M26.84M
Total Debt
4.41M1.25M1.61M2.87M1.23M1.55M
Net Debt
-4.18M-8.13M-6.63M-8.46M-13.05M-7.72M
Total Liabilities
8.56M5.78M7.39M8.40M5.70M5.73M
Stockholders Equity
19.01M18.82M21.10M20.53M21.13M21.11M
Cash FlowFree Cash Flow
-761.00K1.94M-1.25M-1.94M5.55M5.09M
Operating Cash Flow
1.09M2.08M-1.02M-1.60M5.61M5.31M
Investing Cash Flow
-1.77M-133.00K-290.00K-846.00K-59.00K-215.00K
Financing Cash Flow
-879.00K-782.00K-1.85M-500.00K-476.00K-4.39M

Crescita Therpeutc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.51
Price Trends
50DMA
0.57
Negative
100DMA
0.58
Negative
200DMA
0.57
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
38.08
Neutral
STOCH
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CTX, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.57, and below the 200-day MA of 0.57, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.08 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CTX.

Crescita Therpeutc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSNEO
67
Neutral
C$322.89M-0.53%5.17%-21.32%82.85%
TSHLS
63
Neutral
C$124.63M-24.49%-8.60%21.06%
TSCTX
54
Neutral
C$10.86M-15.57%-7.56%-334.57%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
TSTH
40
Underperform
$100.24M
6.07%80.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CTX
Crescita Therpeutc
0.51
0.13
34.21%
TSE:TH
Theratechnologies
2.22
0.58
35.37%
TSE:HLS
HLS Therapeutics Inc
4.01
-0.33
-7.60%
TSE:NEO
Neo Performance Materials Inc
7.73
1.18
18.02%

Crescita Therpeutc Corporate Events

Crescita Therapeutics Sees Strong Q3 Revenue Growth
Nov 6, 2024

Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.